January 2, 2024 02:14 PM EST
Pharma

Bey­for­tus ap­proved in Chi­na to pro­tect in­fants from RSV; Il­lu­mi­na in­vestor files class ac­tion suit

Nicole DeFeudis

Editor

Lia DeGroot

As­traZeneca and Sanofi’s Bey­for­tus won an ap­proval in Chi­na to pre­vent RSV low­er res­pi­ra­to­ry tract in­fec­tion in new­borns and in­fants dur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times